Compare GLU & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GLU | HURA |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 131.8M |
| IPO Year | N/A | N/A |
| Metric | GLU | HURA |
|---|---|---|
| Price | $19.93 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 12.4K | ★ 609.3K |
| Earning Date | 01-01-0001 | 02-14-2026 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $0.70 |
| 52 Week High | $15.40 | $5.50 |
| Indicator | GLU | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 78.75 | 27.26 |
| Support Level | $18.36 | $0.70 |
| Resistance Level | $18.65 | $1.07 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 85.96 | 7.45 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.